Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29689259 | 0.86 | CA12 (0.46) | CA12CA14CA2CA1CA7 | |
| SCHEMBL85950 | 0.86 | CA12 (0.46) | CA12CA14CA2CA1CA7 | |
| SCHEMBL1262051 | 0.86 | CA12 (0.46) | CA12CA14CA2CA1CA7 | |
| SCHEMBL1262055 | 0.86 | CA12 (0.46) | CA12CA14CA2CA1CA7 | |
| SCHEMBL18756255 | 0.83 | APLNR (0.41) | CA12CA14APLNRCA2CA1 | |
| SCHEMBL2671597 | 0.82 | APLNR (0.46) | CA12CA14APLNRCA2CA1 | |
| SCHEMBL5325084 | 0.81 | APLNR (0.42) | CA12CA14APLNRCA2CA1 | |
| SCHEMBL6709591 | 0.80 | CA1 (0.46) | CA12CA14APLNRCA2CA1 | |
| SCHEMBL23518432 | 0.79 | CA12 (0.41) | CA12CA14APLNRCA2CA1 | |
| SCHEMBL8356011 | 0.77 | APLNR (0.42) | CA12CA14APLNRCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067988-A1 | Piperididinyl and N-amidinopiperidinyl derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2004-04-08 | — | — | US | disclosed |
| US-6277865-B1 | ANTICOAGULANTS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067988-A1 | Piperididinyl and N-amidinopiperidinyl derivatives | TFPI, F2, SERPINC1 | CA12 3329/4885CA14 3519/4885APLNR 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.